Beijing Boya Research Institution

Beijing Boya Research Institution appears to be the Beijing new-drug R&D and translational medicine center within the Boyalife group rather than a standalone independently branded public biotech company. The Beijing site serves as Boyalife's new drug research center and is described as relying on the Peking University Institute of Molecular Medicine–Boya Joint Translational Medicine Center to advance patented therapies from laboratory research toward clinical use. Within the broader Boyalife platform, the organization works on stem cell, immune cell, exosome, and CAR-T-related programs, supported by automated cell-processing devices and clinical collaboration networks. Publicly described pipeline areas include knee osteoarthritis, gynecologic and immune disorders, vascular and orthopedic indications, and broader regenerative medicine applications. Because disclosures are made mainly at the parent-group level, program-specific details attributable solely to the Beijing Boya Research Institution are limited.